Abstract: Certain Apolipoprotein B Editing Complex 3-related DRMs including reverse transcriptase gene mutations M184I, E138K, M230I, G190E and protease gene mutations M46I, D30N were enriched in hypermutated sequences but not in intact sequences or plasma sequences.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49), V179D (2.0%, 1/49) and P225H (2.0%, 1/49).
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 33722682
2021
International journal of infectious diseases
Abstract: DISCUSSION: Despite high prevalence of M184V/I in antiretroviral therapy (ART) experienced patients, DTG treatment outcomes will likely not be adversely affected by this mutation.
Abstract: DTG-based regimens have to great extent been effective at maintaining viral suppression in treatment experienced PLWH carrying M184V/I.
Abstract: High genetic barrier to the development of resistance associated with DTG and progressive viral suppression in patients switched to DTG-based therapy with M184V/I, may encourage better DTG outcomes and help in curbing increasing levels of HIV drug resistance in LMICs.
Abstract: Lamivudine and emtricitabine associated M184V/I mutation is highly prevalent in PLWH and the majority of HIV infected individuals receiving DTG regimen
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
PMID: 34397746
2021
Journal of acquired immune deficiency syndromes (1999)
Abstract: Overall, 32% were ciswomen, 2% transwomen, and 10% had an M184V/I mutation.
Result: Altogether, 68 participants with baseline NRTI resistance (including 50 with M184V/I) received B/F/TAF during the study and had postswitch virologic data.
Result: At baseline, 13% (44 of 328) in the B/F/TAF group and 16% (26 of 165) in the SBR group had NRTI resistance, including 9% (31 of 328) and 12% (20 of 165) with M184V/I mutations in the B/F/TAF and SBR groups, respectively.
Result: The median age overall
Table: M184V/I
Discussion: Pre-existing NRTI resistance, including the M184V/I mutation, did not impact the efficacy of switching to B/F/TAF.
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.
PMID: 34327247
2021
Open forum infectious diseases
Result: In contrast (Cox model 3), the presence of M184V/I (versus its absence; adjusted hazard ratio [aHR], 3.31; 95% CI, 1.02-10.74; P = .046) and, particularly (Cox
Table: M184V/I
Discussion: However, previous observational studies suggested an increased risk of VF during 3TC-based DT when M184V/I was present in combination with a shorter time of viral suppression.
Discussion: Indeed, M184V/I and TAMs appear to synergize with each other since TAMs alone were not associated with VF.
Discussion: Our study showed that a shorter duration of virological suppression and the presence of M184V/I were independent predictors of VF; however, M184V/I alone was less accurate in predicting the outcome than its combination with TAMs.
Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
Abstract: The most common DRMs were M184I/V (42.2%), followed by V179D/E (37.9%) and K65R (27.2%).
Result: Among the NRTI DRMs, M184I/V (42.2%, 166/393) was the most frequent, followed by K65R (27.2%, 107/393).
Discussion: M184I/V (42.2%) was the most prevalent NRTI-associated mutation, which might be caused by the frequent use of 3TC in ART-experienced patients.
Discussion: A high frequency of K65R plus M184V/I (15.0%) was observed in this study, and K65R plus M184 V/I appeared sufficient to abrogate the PMID: 34584606
2021
The Pan African medical journal
Introduction: These mutations included M184V, K65R,D67N,K70R,K219Q,Q151M, T215F, M41L, T69N, V75M, M41L, T69N, V75M, D67G, V75M, M184I, T215N, M41LM, T215N, K219N,210W, T215Y as NRT
Table: M184I
Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.
Abstract: NRTI primary mutations M184 V/I and K65R/E/N were found in 28.8% and 8.9% of subjects respectively, while NNRTI primary mutations K103N/S, G190A, and Y181C were found in 21.0%, 14.6%, and 10.9% of subjects.
Discussion: Similar M184 V/I predominance trends (81.2%) have been reported in Uganda.
Discussion: The fact that 3TC is a backbone for most Kenyan ART-regimens explains this predominance of M184 V/I.
Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Abstract: The TDF/FTC DRMs included K65R (8/13), M184I/V (5/13), and Y115F (2/13).
Introduc
Introduction: The main drug resistance mutations (DRMs) to TDF/FTC include K65R and M184I/V, but the global incidence was rather low in HIV ART-naive patients.
Result: K65R is known to confer high-level resistance to TDF and intermediate-level resistance to FTC, while M184I/V confers high-level resistance to FTC and 3TC and low-level resistance to abacavir (ABC).
Result: The mutations included K65R (61.5%, 8/13), M184I/V (38.5%, 5/13), and Y115F (2/13).
HIV mutation literature information.
PMID: 
2021
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT